N/A N=127 The Human Papilloma Virus Effect on Sexual Life
Human Papillomavirus Infection
Primary: Female Sexual Function Index (FSFI) Score — 0.8; 1.2; 0.9; 0.7 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=225 HPV Vaccination Study in Postpartum Women
HPV · Immunization · Human Papilloma Virus
Primary: Immunogenicity of a Two-dose 9-valent HPV Vaccination as Assessed by Antibody Titer — 7177.6 mMU/mL
N/A N=156 Typing of Human Papilloma Virus (HPV) From Female Genital Warts
Genital Warts · Human Papilloma Virus
Primary: HPV DNA and HIV Status — 96; 19; 4; 5 participants
Phase 3 N=666 Human Papilloma Virus (HPV) Vaccine Immunogenicity and Safety Trial in Young and Adult Women With GSK Biologicals' HPV-16/18
Infections, Papillomavirus
Primary: Number of Seroconverted Subjects for Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies, in Women 15 to 25 Years of…
N/A N=329 Human Papillomavirus Infection and Virus Genotyping in Uterine Cervix Cancer in Venezuela
Cervical Cancer
Primary: HPV Identification — 95; 142; 78 biopsies
Phase 4 N=19 Use of Cidofovir for Recurrent Respiratory Papillomatosis
Recurrent Respiratory Papillomatosis
Primary: Change in Papilloma Severity — 13.2; 12; 3.7; 3.6 scores on a scale
Phase 3 N=770 Human Papillomavirus (HPV) Vaccine Consistency and Non-inferiority Trial in Young Adult Women
Papillomavirus Type 16/18 Infection · Cervical Intraepithelial Neoplasia
Primary: Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies — 1440.4; 1903.7; 3861.7; 1397.5 EL.U/mL
Phase 2 N=383 Human Papillomavirus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Biologicals Novel HPV Vaccine
Infections, Papillomavirus · Papillomavirus Vaccines
Primary: Number of Seroconverted Subjects Against Human Papillomavirus-16 (HPV-16) Antibodies. — 27; 10; 9; 8 subjects
Phase 2 N=21 Pembrolizumab for HPV-associated Recurrent Respiratory Papilloma Patients
Recurrent Respiratory Papillomatosis
Primary: Overall Response Rate Via Endoscopic Lesional Burden Score and/or RECIST — 21 Participants
Phase 2 N=319 Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
HIV Infections · Sexually Transmitted Diseases
Primary: Percentage of Participants With HPV6 Antibody Development From Seronegative Status at Baseline to Seropositive Status a Month After Completion of HPV Vaccination Series…
Phase 2 N=383 Human Papilloma Virus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Bio's Novel HPV Vaccine.
Infections, Papillomavirus
Primary: Number of Seroconverted Subjects for Anti-Human Papillomavirus (Anti-HPV)-16 at Month 7 — 62; 27; 31; 23 Participants
N/A N=15 Human Papillomatosis Genotyping of Children in Thailand
Recurrent Laryngeal Papillomatosis · Human Papilloma Virus
Primary: Human Papillomavirus Genotypes — 6; 9 participants
Phase 2 N=9 M7824 in People With Recurrent Respiratory Papillomatosis
Recurrent Respiratory Papillomatosis · Respiratory Papillomatosis · Laryngeal Papilloma, Recurrent
Primary: Proportion of Participants With a Complete Response — 0; 0 proportion of participants
Phase 3 N=52 Effectiveness Study of Human Papilloma Virus (HPV) Vaccines to Prevent Recurrence of Genital Warts
Genital Warts
Primary: Change in the Maximum Size of the Genital Wart Lesion Over the Trial Period (as Measured in mm) — 8; 6; 11; 7 Participants
Phase 2 N=109 Human Papillomavirus Vaccine Therapy in Treating Men With HIV-1 Infection
Infection · Precancerous Condition
Primary: Occurrence of ≥ Grade 3 Adverse Events Probably or Definitely Related to the Vaccine — 0 participants
Phase 4 N=372 Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) Study
Human Papillomavirus Infection
Primary: HPV Incidence Rates, Expressed as Incident Infections/1000 Infection-months at Risk. These Were Calculated Separately for Females and Males Across the Four Vaccine…
N/A N=467 HPV Test-and-Treat-Strategy Versus Cytology-based Strategy for Prevention of CIN2+ in HIV-Infected Women
HIV-1 Infection
Primary: Cumulative Rate of Cervical Intraepithelial Neoplasia (CIN2+) (CIN2, CIN3 or Invasive Cancer) by Week 130 — 24.9; 26.5 Events per 100 persons
Phase 2 N=29 Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers
Cervical Cancer · Oropharyngeal Cancer · Vaginal Cancer
Primary: Number of Participants With an Objective Clinical Response — 3; 2; 2; 0 Participants
Phase 2 N=2 Intralesional HPV Vaccine for Condylomata
Human Papilloma Virus · Warts · Warts, Genital
Primary: Change in Wart Number — 0.5 warts
Phase 2 N=13 Avelumab for People With Recurrent Respiratory Papillomatosis
Recurrent Respiratory Papillomatosis · Juvenile Laryngeal Papilloma · Laryngeal Papilloma, Recurrent
Primary: Number of Patients With Laryngotracheal Recurrent Respiratory Papillomatosis (RPP) Who Achieve a Complete Response With Avelumab as Measured by Derkay Score Calculated…
Phase 2 N=32 INO-3107 With Electroporation (EP) in Participants With HPV-6- and/or HPV-11-Associated Recurrent Respiratory Papillomatosis (RRP)
Respiratory Papillomatosis
Primary: Percentage of Participants With at Least One Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs — 33.3; 66.7; 75.0; 62.5 percentage of participants
Phase 3 N=100 Complementary Testing to Evaluate Immunogenicity of Human Papillomavirus (HPV) Vaccine (580299) in Healthy Female Subjects Aged >/= 26 Years
Infections, Papillomavirus
Primary: Number of Cytokine-positive CD4/CD8 Cells Per Million in Tests Producing at Least 2 Different Cytokines — 877.4; 19.5; 738.5; 22.3 cells per million CD4/CD8 T-cells
N/A N=33 HPV DNA Testing Through Mobile Mammography Unit
Cervical Cancer
Primary: Acceptability of Self-Collection Paired With Mobile Mammography — 33 Participants
Phase 3 N=798 Evaluation of the Immune Responses of GSK Biologicals' HPV Vaccine Following Manufacturing Process Adaptation.
Infections, Papillomavirus · Papillomavirus Vaccines
Primary: Number of Seroconverted (SCR) Subjects for Anti-Human Papillomavirus Type 16 (Anti-HPV-16) and Anti-Human Papillomavirus Type 18 (Anti-HPV-18) — 118; 127; 126; 371…
Phase 1 N=20 Bevacizumab for Treatment of Recurrent Respiratory Papillomatosis (RRP)
Recurrent Respiratory Papillomatosis
Primary: The Primary Activity Variable Was the Recurrence of Recurrent Respiratory Papillomatosis (RRP) in Bevacizumab Treated and the Un-treated Vocal Fold in the Same Patient…
Phase 4 N=56 Postpartum HPV Vaccination
HPV-Related Malignancy
Primary: Patient Indication of Willingness to Accept the Vaccine Based on Survey — 56 Participants
N/A N=150 Human Papillomavirus (HPV) Types Present in External Genital Warts (EGW) in the Argentinean Population
Condylomata Acuminata
Primary: Human Papillomavirus (HPV) Types in External Genital Warts (EGW) — 80; 12.66; 0.66; 2 percentage of participants
Phase 3 N=18,644 Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18
Infections, Papillomavirus
Primary: Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)2+ Associated With HPV-16 and/or -18 Cervical Infection in Subjects HPV DNA…
Phase 1 N=18 Study With Candida Antigen for Treatment of Warts
Warts · HPV
Primary: Number of Participants With Clinical Resolution of Injected Wart — 9; 1; 1 Participants
Phase 2 N=33 Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)
Vulvar High Grade Squamous Intraepithelial Lesion (HSIL) · Vulvar Dysplasia · Vulvar Intraepithelial Neoplasia (VIN)
Primary: Percentage of Participants With No Histologic Evidence of Vulvar HSIL and No Evidence of HPV-16 and/or HPV-18 in Vulvar Tissue Samples — 15.0; 37.5 percentage of…